Moxifloxacin Al (Moxifloxacin)

Moxifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA supercoiling and replication. By blocking these targets, the drug prevents bacterial DNA synthesis and leads to rapid bacterial cell death across a broad spectrum of Gram‑positive and Gram‑negative organisms.

The prescribed dose of Moxifloxacin Al is determined by the treating physician based on the specific infection, patient age, renal function and other clinical factors. Dosage regimens may differ between indications, and the prescriber will provide the appropriate instructions.

Safety data for moxifloxacin in pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To request Moxifloxacin Al, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Moxifloxacin offers a broader spectrum against Gram‑positive organisms and better activity against atypical respiratory pathogens compared with older fluoroquinolones such as ciprofloxacin. It also has a once‑daily dosing schedule, which can improve patient adherence, but shares class‑related safety considerations.

Moxifloxacin Al tablets should be stored at temperatures below 25 °C, in the original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and do not use after the expiry date printed on the label.

Moxifloxacin Al is taken orally as a tablet with a full glass of water. It may be taken with or without food, but patients should follow the prescriber’s instructions regarding timing relative to meals to ensure optimal absorption.

Serious adverse events include tendon rupture or tendinitis, QT interval prolongation that can lead to arrhythmias, severe allergic reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis. Patients should seek immediate medical attention if they experience unexplained tendon pain, palpitations, or signs of a severe allergic reaction.

Moxifloxacin Al is contraindicated in individuals with a known hypersensitivity to moxifloxacin or other fluoroquinolones, a history of tendon disorders related to fluoroquinolone use, or a documented prolonged QT interval. Caution is also advised for patients with severe renal impairment or those taking medications that prolong the QT interval.